AR047383A1 - Derivados de acilaminotiazol, su preparacion y su aplicacion en terapeutica - Google Patents
Derivados de acilaminotiazol, su preparacion y su aplicacion en terapeuticaInfo
- Publication number
- AR047383A1 AR047383A1 ARP050100110A ARP050100110A AR047383A1 AR 047383 A1 AR047383 A1 AR 047383A1 AR P050100110 A ARP050100110 A AR P050100110A AR P050100110 A ARP050100110 A AR P050100110A AR 047383 A1 AR047383 A1 AR 047383A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- phenyl
- alkyl
- alkoxy
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Reivindicacion 1: compuesto que responde a la formula general (1): en la cual, R1 representa o bien un alquilo C1-6 eventualmente sustituido por uno a tres sustituyentes elegidos entre un halogeno, un trifluorometilo, un hidroxi, un alcoxi C1-6, un tioalquilo C1-6, un tiofeno o un fenilo; o bien un cicloalquilo C3-7, un tiofeno, un benzotiofeno, un piridinilo, un furanilo o un fenilo; dichos grupos fenilo están eventualmente sustituidos por uno a tres sustituyentes elegidos entre un átomo de halogeno, un alquilo C1-6, un alcoxi C1-6, un hidroxi, un metilendioxi, un fenoxi o un benciloxi o un trifluorometilo; R2 y R??2 representan, independientemente entre sí, un átomo de H, un átomo de halogeno, un hidroxi, un alcoxi C1-3, un alquilo C1- 3, un cicloalquilo C3-7, un grupo O-C(O)-alquilo C1-6, o R2 y R??2 forman juntos un grupo oxo; R3 representa un átomo de H, un alquilo C1-6 eventualmente sustituido por un hidroxi, un cicloalquilo C1-6 o un alcoxi C1-3; R4 o R5 representa, independientemente entre sí, un átomo de H, un alquilo C1-7, un trifluorometilo, un grupo L o un grupo Z; G representa un alquilo C1-7 o un enlace simple; M representa un cicloalquilo C3-7, un fenilo, un naftilo o un piridinilo; el grupo M está eventualmente sustituido por uno o varios grupos elegidos entre un átomo de halogeno, un grupo hidroxi, un alquilo C1-3, un alcoxi C1-3, un trifluorometilo, un trifluorometoxi, un -O-CHF2; J representa un átomo de H o un grupo -Y-K; Y representa un enlace simple, un átomo de O, de S, un grupo alquileno C1-4, O-alquileno C1-4, alquileno C1-4-O- o -N(W)-, el grupo alquileno C1-4 está eventualmente sustituido por un grupo hidroxi o alcoxi C1-3; W representa, o bien un átomo de H, o bien un alquilo C1-3 eventualmente sustituido por un fenilo, o bien un fenilo; K representa un grupo fenilo o piridinilo, y el grupo K está eventualmente sustituido por uno o varios grupos elegidos entre un átomo de halogeno, un grupo hidroxi, un alquilo C1- 3, un alcoxi C1-3, un trifluorometilo, un trifluorometoxi, un -O-CHF2; a condicion de que al menos un grupo R4 o R5 represente un grupo Z; Z representa un grupo CN, SO2NR6R7, o un grupo heteroaromático; dicho grupo heteroaromático está eventualmente sustituido por un grupo R8; R8 representa o bien un alquilo C1-4, a su vez sustituido eventualmente por un CN, un fenilo o un fenoxi; o bien un fenilo; dichos grupos fenilo y fenoxi están eventualmente sustituidos por 1 a 3 grupos elegidos entre un átomo de halogeno, un alquilo C1-3, un alcoxi C1-3, un trifluorometilo; R6 y R7 representan, independientemente entre sí, o bien un átomo de H, o bien un grupo alcoxi C1-6, eventualmente sustituido por un cicloalquilo C3-7, un cicloalquenilo C3-7, alcoxi C1-3, un fenilo, un naftalenilo, un morfolinilo o un piridinilo; o bien un cicloalquilo C3-7, alcoxi C1-6, un fenilo o un indanilo dichos grupos cicloalquilo C3-7, cicloalquenilo C3-7, fenilo, naftalenilo, morfolinilo, piridinilo e indanilo están eventualmente sustituidos por uno o dos grupos elegidos entre un alquilo C1-3, un hidroxi, un alcoxi C1-3, un fenilo o un átomo de halogeno; o R6 y R7, con el átomo de N que los lleva, forman un ciclo aziridina, azetidina, pirrolidina, piperidina, morfolino o benzopiperidina; en estado de base, de sal de adicion con un ácido, de hidrato o de solvato.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0400388A FR2865207B1 (fr) | 2004-01-16 | 2004-01-16 | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| FR0408116A FR2873374B1 (fr) | 2004-07-22 | 2004-07-22 | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047383A1 true AR047383A1 (es) | 2006-01-18 |
Family
ID=34828646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100110A AR047383A1 (es) | 2004-01-16 | 2005-01-13 | Derivados de acilaminotiazol, su preparacion y su aplicacion en terapeutica |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7371770B2 (es) |
| EP (1) | EP1709018B1 (es) |
| JP (1) | JP4813371B2 (es) |
| AR (1) | AR047383A1 (es) |
| AT (1) | ATE517098T1 (es) |
| DK (1) | DK1709018T3 (es) |
| IL (1) | IL176772A0 (es) |
| PT (1) | PT1709018E (es) |
| SI (1) | SI1709018T1 (es) |
| TW (1) | TWI350287B (es) |
| WO (1) | WO2005073202A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1709041A1 (fr) * | 2004-01-16 | 2006-10-11 | Sanofi-Aventis | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| EP1709018B1 (fr) * | 2004-01-16 | 2011-07-20 | Sanofi-Aventis | Derives d'acylaminothiazole et leur application comme inhibiteurs de beta-amyloide |
| JP2007119416A (ja) * | 2005-10-31 | 2007-05-17 | Bayer Cropscience Ag | 殺虫性２−アシルアミノチアゾール−４−カルボキサミド類 |
| EA200801716A1 (ru) * | 2006-01-18 | 2009-04-28 | Амген Инк. | Тиазольные соединения и их применение |
| WO2007116106A1 (es) * | 2006-04-12 | 2007-10-18 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina |
| US7919504B2 (en) * | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| TW200922564A (en) * | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| WO2010012793A1 (en) * | 2008-08-01 | 2010-02-04 | Bayer Cropscience Sa | Fungicide aminothiazole derivatives |
| WO2010075542A1 (en) | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
| KR101095630B1 (ko) | 2009-06-17 | 2011-12-19 | 주식회사 이노파마스크린 | 베타 아밀로이드 펩타이드와 ｖｅｇｆ의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제 |
| EP2273273A1 (en) | 2009-07-11 | 2011-01-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease |
| EP2492269A4 (en) * | 2009-10-19 | 2013-08-07 | Taisho Pharmaceutical Co Ltd | aminothiazole |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000024392A1 (fr) * | 1998-10-26 | 2000-05-04 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteur de la formation de beta-amyloide |
| AR039059A1 (es) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
| FR2842523A1 (fr) * | 2002-07-17 | 2004-01-23 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| WO2004033439A1 (en) * | 2002-10-09 | 2004-04-22 | Pfizer Products Inc. | Thiazole compounds for the treatment of neurodegenerative disorders |
| EP1709018B1 (fr) * | 2004-01-16 | 2011-07-20 | Sanofi-Aventis | Derives d'acylaminothiazole et leur application comme inhibiteurs de beta-amyloide |
-
2005
- 2005-01-07 EP EP05717377A patent/EP1709018B1/fr active Active
- 2005-01-07 WO PCT/FR2005/000029 patent/WO2005073202A1/fr not_active Application Discontinuation
- 2005-01-07 AT AT05717377T patent/ATE517098T1/de active
- 2005-01-07 DK DK05717377.5T patent/DK1709018T3/da active
- 2005-01-07 PT PT05717377T patent/PT1709018E/pt unknown
- 2005-01-07 JP JP2006548340A patent/JP4813371B2/ja not_active Expired - Fee Related
- 2005-01-07 SI SI200531394T patent/SI1709018T1/sl unknown
- 2005-01-11 TW TW094100684A patent/TWI350287B/zh not_active IP Right Cessation
- 2005-01-13 AR ARP050100110A patent/AR047383A1/es unknown
-
2006
- 2006-07-10 IL IL176772A patent/IL176772A0/en unknown
- 2006-07-14 US US11/457,490 patent/US7371770B2/en not_active Expired - Fee Related
-
2008
- 2008-03-20 US US12/051,924 patent/US7759377B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE517098T1 (de) | 2011-08-15 |
| EP1709018B1 (fr) | 2011-07-20 |
| PT1709018E (pt) | 2011-10-24 |
| EP1709018A1 (fr) | 2006-10-11 |
| US20080176911A1 (en) | 2008-07-24 |
| US7759377B2 (en) | 2010-07-20 |
| IL176772A0 (en) | 2006-10-31 |
| WO2005073202A1 (fr) | 2005-08-11 |
| TWI350287B (en) | 2011-10-11 |
| JP2007520478A (ja) | 2007-07-26 |
| DK1709018T3 (da) | 2011-11-14 |
| SI1709018T1 (sl) | 2011-11-30 |
| US20060293366A1 (en) | 2006-12-28 |
| US7371770B2 (en) | 2008-05-13 |
| JP4813371B2 (ja) | 2011-11-09 |
| TW200533659A (en) | 2005-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047383A1 (es) | Derivados de acilaminotiazol, su preparacion y su aplicacion en terapeutica | |
| AR046422A1 (es) | Acidos carboxilicos macrociclicos y acilsulfonamidas como inhibidores de la replicacion del vhc | |
| AR046982A1 (es) | Derivados de 1-piperazin- y 1-homopiperazin-carboxilatos, su preparacion y su aplicacion en terapeutica | |
| AR041459A1 (es) | Derivados de indazolcarboxamidas su preparacion y su utilizacion en terapeutica | |
| AR042525A1 (es) | Derivados de pirrolo-pirazoles sustituidos como inhibidores de quinasa | |
| ECSP045369A (es) | Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica | |
| AR040570A1 (es) | Deriados de acilaminotiazol, su preparacion y su aplicacion en terapeutica | |
| AR048778A1 (es) | Derivados de pirrolidinilo como inhibidores de 11-beta hidroxiesteroide deshidrogenasa | |
| AR047384A1 (es) | Derivados de tipo ariloxialquilcarbamatos, su preparacion y su aplicacion en terapeutica | |
| ATE487717T1 (de) | Imidazo- und triazolopyridine als inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1 | |
| AR048375A1 (es) | Indazol-o-glucosidos sustituidos | |
| AR054195A1 (es) | Derivados de indol como inhibidores de la fosfolipasa a2 citosolica y composicion farmaceutica que los contiene | |
| AR073774A1 (es) | Compuestos antibioticos oxazolidinona triciclicos | |
| AR058077A1 (es) | Derivados de acidos fenoxiaceticos | |
| CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| AR058006A1 (es) | Mimeticos de glucocorticoides, composiciones farmaceiticas y usos de los mismos | |
| AR068503A1 (es) | Derivados de amidas sustituidas, composicion farmaceutica y usos. | |
| CO5601027A2 (es) | Derivados de imidazol-4-il-etinil-piridina | |
| AR048004A1 (es) | Nuevos esteres de quinuclidina cuaternizados | |
| AR076228A1 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| AR063420A1 (es) | Derivados de 2-ciano-4-pirimidinil sustituidos,proceso de preparacion de los mismos,medicamentos que los contienen y su uso para el tratamiento de la malaria. | |
| HN2005000239A (es) | Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica | |
| RS53677B1 (en) | TRIAZOLOPYRIDINE UNITS | |
| CO5031250A1 (es) | Compuesto farmaceutico | |
| AR039059A1 (es) | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |